NASDAQ · SOPH
SOPHiA GENETICS S.A.
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
Loading market information…
NASDAQ · DH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Definitive Healthcare Corp.’s quoted price sits in the lower half of its reported 52-week range, 62.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Definitive Healthcare Corp.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.04. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Definitive Healthcare Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Definitive Healthcare Corp. (DH), operating through its various subsidiaries, offers specialized commercial intelligence solutions for the U.S. healthcare industry. The company's services furnish essential data on healthcare providers and their activities, enabling clients to navigate critical business processes, from the early stages of product development to strategic market entry planning and effective sales and marketing execution. Its sophisticated platform incorporates sixteen distinct intelligence modules. These modules are designed to support key functional domains such as sales optimization, marketing initiatives, clinical research, new product creation, strategic planning, human capital acquisition, and the oversight of physician networks. Definitive Healthcare caters to a broad spectrum of clients, including biopharmaceutical firms, medical device manufacturers, healthcare information technology companies, and direct healthcare providers. Additionally, its clientele extends to diverse organizations within the wider healthcare ecosystem, such as staffing and commercial real estate companies, financial institutions, and other related entities. Founded in 2011, Definitive Healthcare Corp. is headquartered in Framingham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | $0.05+150.0% vs estimate | $59.19M+1.73% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | $0.08+14.29% vs estimate | $62.29M+2.79% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | $0.10+25.0% vs estimate | $62.70M+3.49% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $1.10.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.97+$0.10 (+1.27%)
SOPHiA GENETICS S.A.’s quoted price sits in the upper half of its reported 52-week range, 11.25% below the high.
$23.49+$0.02 (+0.09%)
NRC Health’s quoted price sits in the upper half of its reported 52-week range, 3.73% below the high.
$2.93-$0.02 (-0.68%)
Editas Medicine, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.63% below the high.
$26.24$0.00 (0.0%)
TruBridge, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
$18.50$0.00 (0.0%)
Simulations Plus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.95% below the high.
$5.85-$0.04 (-0.68%)
Kyverna Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
$1.59+$0.07 (+4.28%)
Cabaletta Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.53% below the high.
$11.78+$1.60 (+15.72%)
Spok Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.2% below the high.
